BC Extra | Oct 25, 2012
Financial News

Aclaris raises $21M

Dermatology company Aclaris Therapeutics Inc. (Malvern, Pa.) raised $21 million in a series A round led by Vivo Ventures and Fidelity Biosciences. Sofinnova Ventures participated. Aclaris is developing topical dermatology product A-101, which is in...
BioCentury | Jan 2, 2012
Finance

Cross-border pollination

Vivo Ventures will invest more in China than ever before with its newly closed, oversubscribed $375 million fund. The firm's seventh fund was raised in about nine months and had an original target of $350...
BioCentury | Oct 17, 2011
Finance

All chips on life sciences

Sofinnova Ventures was to announce on Monday this week that it closed an oversubscribed $440 million fund, its first dedicated entirely to life sciences . Sofinnova's eighth fund initially had a $325 million target, with an...
BC Week In Review | Jul 25, 2011
Company News

Vicept, Allergan deal

Allergan will acquire Vicept for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a topical cream targeting alpha adrenergic receptors on small...
BioCentury | Jul 25, 2011
Finance

Unsustainable blip

A report showing a 46% quarter over quarter rise in VC funding for biotech companies is just a blip on the screen. Despite the report's headline numbers, VCs think the real story still is the...
BC Extra | Jul 20, 2011
Company News

Allergan buying Vicept

Allergan Inc. (NYSE:AGN) will acquire dermatology company Vicept Therapeutics Inc. (Malvern, Pa.) for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a...
BC Week In Review | May 16, 2011
Company News

Yaupon management update

Yaupon Therapeutics Inc. , Radnor, Pa.   Business: Cancer, Neurology   Hired: Steve Tullman as chairman and CEO, he is the chairman of Vicept Therapeutics Inc. , and co-founder and former president and CEO of Ception Therapeutics...
BC Week In Review | Apr 25, 2011
Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-206 trial in 85 patients with moderate to severe erythema showed that V-101 met the primary endpoint of significantly reducing facial erythema from baseline over a 12 hour period...
BC Week In Review | Jan 17, 2011
Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-202 trial in 183 patients with moderate to severe erythema showed that once-daily 0.1% and 0.15% V-101 for 28 days met the primary endpoint of significantly reducing facial erythema...
BC Week In Review | Aug 9, 2010
Clinical News

V-101: Phase I data

Preliminary data from a double-blind, crossover, U.S. Phase I trial in 22 patients with rosacea showed that V-101 had a side effect profile similar to that of placebo and significantly improved moderate to severe erythema...
Items per page:
1 - 10 of 12
BC Extra | Oct 25, 2012
Financial News

Aclaris raises $21M

Dermatology company Aclaris Therapeutics Inc. (Malvern, Pa.) raised $21 million in a series A round led by Vivo Ventures and Fidelity Biosciences. Sofinnova Ventures participated. Aclaris is developing topical dermatology product A-101, which is in...
BioCentury | Jan 2, 2012
Finance

Cross-border pollination

Vivo Ventures will invest more in China than ever before with its newly closed, oversubscribed $375 million fund. The firm's seventh fund was raised in about nine months and had an original target of $350...
BioCentury | Oct 17, 2011
Finance

All chips on life sciences

Sofinnova Ventures was to announce on Monday this week that it closed an oversubscribed $440 million fund, its first dedicated entirely to life sciences . Sofinnova's eighth fund initially had a $325 million target, with an...
BC Week In Review | Jul 25, 2011
Company News

Vicept, Allergan deal

Allergan will acquire Vicept for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a topical cream targeting alpha adrenergic receptors on small...
BioCentury | Jul 25, 2011
Finance

Unsustainable blip

A report showing a 46% quarter over quarter rise in VC funding for biotech companies is just a blip on the screen. Despite the report's headline numbers, VCs think the real story still is the...
BC Extra | Jul 20, 2011
Company News

Allergan buying Vicept

Allergan Inc. (NYSE:AGN) will acquire dermatology company Vicept Therapeutics Inc. (Malvern, Pa.) for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a...
BC Week In Review | May 16, 2011
Company News

Yaupon management update

Yaupon Therapeutics Inc. , Radnor, Pa.   Business: Cancer, Neurology   Hired: Steve Tullman as chairman and CEO, he is the chairman of Vicept Therapeutics Inc. , and co-founder and former president and CEO of Ception Therapeutics...
BC Week In Review | Apr 25, 2011
Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-206 trial in 85 patients with moderate to severe erythema showed that V-101 met the primary endpoint of significantly reducing facial erythema from baseline over a 12 hour period...
BC Week In Review | Jan 17, 2011
Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-202 trial in 183 patients with moderate to severe erythema showed that once-daily 0.1% and 0.15% V-101 for 28 days met the primary endpoint of significantly reducing facial erythema...
BC Week In Review | Aug 9, 2010
Clinical News

V-101: Phase I data

Preliminary data from a double-blind, crossover, U.S. Phase I trial in 22 patients with rosacea showed that V-101 had a side effect profile similar to that of placebo and significantly improved moderate to severe erythema...
Items per page:
1 - 10 of 12